NCT02262338View on ClinicalTrials.gov

Safety and Dose Ranging Study of Insulin Receptor MoAb-IDS Fusion Protein in Patients With Hunter Syndrome

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

March 27, 2017

Study Completion Date

March 27, 2017

Conditions
Mucopolysaccharidosis II
Interventions
DRUG

AGT-182

Recombinant HIRMAb-IDS

Trial Locations (5)

30033

Emory University, Decatur

92868

Children's Hospital of Orange County, Orange

94609

Children's Hospital Oakland, Oakland

Unknown

ZKJM MC University of Mainz, Mainz

Institute of Human Genetics, National Inst of Health, University of the Philippines, Manila

Sponsors

Lead Sponsor

ArmaGen, Inc
All Listed Sponsors
lead

ArmaGen, Inc

INDUSTRY